| Identification | Back Directory | [Name]
N-(3-((2-((4-(4-methylpiperazin-1-yl)phenyl)amino)thieno[3,2-d]pyrimidin-4-yl)oxy)phenyl)acrylamide | [CAS]
1842366-97-5 | [Synonyms]
Olmutinib hydrochloride
N-[3-[2-[4-(4-methylpiperazin-1-yl)anilino]thieno[3,2-d]pyrimidin-4-yl]oxyphenyl]prop-2-enamide | [Molecular Formula]
C26H27ClN6O2S | [MOL File]
1842366-97-5.mol | [Molecular Weight]
523.05 |
| Hazard Information | Back Directory | [Uses]
Olmutinib hydrochloride is an orally active and irreversible third EGFR tyrosine kinase inhibitor that binds to a cysteine residue near the kinase domain. Olmutinib hydrochloride is used for NSCLC[1][2]. | [References]
[1] Kim ES, et al. Olmutinib: First Global Approval. Drugs. 2016 Jul;76(11):1153-7. DOI:10.1007/s40265-016-0606-z
[2] Mohamed W. Attwa, et al. Detection and characterization of olmutinib reactive metabolites by LC‐MS/MS: Elucidation of bioactivation pathways. Journal of Separation science. 18 November 2019. |
|
|